What is CJC-1295 in research?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) developed in DAC and non-DAC forms. It is studied in controlled laboratory settings for its ability to stimulate endogenous growth hormone release and influence GH–IGF-1 axis signaling.

How does CJC-1295 (DAC and no-DAC) function in laboratory studies?

In research models, CJC-1295 binds to GHRH receptors on pituitary somatotrophs, promoting pulsatile growth hormone secretion and downstream IGF-1 production. DAC conjugation extends the peptide's half-life, leading to a longer duration of GH and IGF-1 elevation compared with native GHRH.

Is CJC-1295 considered a therapeutic product?

No. CJC-1295 provided by The Peptide Company is intended strictly for laboratory and in-vitro research use. It is not a therapy, drug, supplement, or product for human or clinical use.

What research applications involve CJC-1295?

CJC-1295 is examined in experimental studies of GH–IGF-1 axis regulation, endocrine aging models, metabolic signaling, tissue repair, and pulsatile hormone release dynamics under controlled laboratory conditions.

Does CJC-1295 affect growth hormone pulsatility in studies?

Yes. Preclinical and clinical research has shown that CJC-1295, particularly the DAC-conjugated form, can increase growth hormone pulse amplitude and extend the duration of elevated GH and IGF-1 levels while preserving physiologic pulsatile secretion patterns.

How is CJC-1295 typically handled in research settings?

CJC-1295 is generally supplied as a lyophilized powder and stored away from light and moisture. After reconstitution according to laboratory protocols, it is kept refrigerated and used only within institutional laboratory or in-vitro research workflows.

Can CJC-1295 be used by consumers or self-administered?

No. CJC-1295 is not intended for self-administration or consumer use. It is reserved exclusively for controlled laboratory and in-vitro research environments.

CJC-1295: GHRH Analog, DAC Conjugation, and Growth Hormone Pulsatility in Research

Daniel Attalla
Nov 17, 2025
2 min read

3D molecular structure artwork of CJC-1295 shown in The Peptide Company’s charcoal and orange research branding

Introduction

Growth hormone (GH) release is governed by a tightly regulated endocrine axis involving GHRH, somatostatin, and feedback from GH and IGF-1. CJC‑1295 represents a family of GHRH analog constructs used in research to explore GH pulsatility, endocrine regulation, and tissue signaling dynamics. This article outlines the biology of the GHRH receptor, followed by detailed sections on CJC‑1295 with DAC and CJC‑1295 without DAC.

What Is CJC‑1295?

CJC‑1295 is a synthetic analog of growth hormone releasing hormone (GHRH) designed to bind the GHRH receptor on anterior pituitary somatotrophs. It enhances endogenous GH secretion in a physiological, pulse‑based manner. Two primary constructs exist: CJC‑1295 with DAC (Drug Affinity Complex) and CJC‑1295 without DAC (Mod GRF 1‑29). Both utilize the same receptor system but differ in structural stability and duration.

CJC‑1295 With DAC

The DAC component allows reversible binding to plasma proteins such as albumin, increasing stability and circulation time. This provides prolonged GHRH receptor stimulation without eliminating the natural pulsatile nature of GH release. DAC‑modified constructs are used to study extended GH/IGF‑1 signaling and chronic endocrine modulation in research settings.

CJC‑1295 Without DAC (Mod GRF 1‑29)

Mod GRF 1‑29 is a 29‑amino acid fragment of GHRH with structural substitutions that increase stability. Without DAC, it does not bind albumin and therefore produces a shorter-lived GHRH signal. This makes it valuable for studying acute GH responses, timing dynamics, and pulse behavior in controlled experiments.

Comparative Overview

CJC‑1295 with DAC and Mod GRF 1‑29 both activate the GHRH receptor but differ in duration and kinetic emphasis. DAC‑modified constructs allow sustained receptor engagement, while Mod GRF 1‑29 provides rapid, discrete signaling useful for timing-based research.

Synergy and Related Research

GHRH analogs are often studied alongside other endocrine peptides. Tesamorelin provides a useful structural comparison as another GHRH analog, while ghrelin receptor agonists such as GHRP‑2 or Ipamorelin act through a separate pathway (GHSR). IGF‑1 LR3 is frequently examined downstream for mapping GH‑IGF signaling behavior.

Summary

CJC‑1295 provides two structurally related tools for studying GH pulsatility and endocrine signaling. DAC‑modified CJC‑1295 allows extended receptor presence, while Mod GRF 1‑29 enables investigation of acute GH pulse patterns. Together, they support research into growth signaling, endocrine timing, and tissue regulation.

CJC‑1295 With DAC vs Without DAC (Research Comparison)

Feature	CJC‑1295 With DAC	CJC‑1295 Without DAC (Mod GRF 1‑29)
Structural Modification	Includes Drug Affinity Complex	No DAC; modified GHRH(1‑29)
Albumin Binding	Yes, reversible	Minimal to none
Circulation Duration	Prolonged	Short, pulse‑like
GH Pattern	Extended stimulation window	Sharp, discrete GH pulses
Research Focus	Long-term GH/IGF‑1 studies	Timing and acute GH response

Educational & Research Disclaimer

This article is for educational and research purposes only. No medical advice or clinical claims are made. Compounds discussed are not approved for human use and are intended exclusively for laboratory research.